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Abstract
This study was performed to test whether the risk of developing chronic widespread pain (CWP) in those with regional pain was
augmented in those with symptoms of neuropathic pain (NP). Persons free of CWP completed the Douleur Neuropathique 4 (scores
$3 indicating NP); demographics; Hospital Anxiety and Depression scale; Pittsburgh Sleep Quality Index; and pain medications.
Participants were classified as having no pain, regional pain with no symptoms of NP (NP), or regional pain with symptoms of NP
(NP). At the 12-month follow-up, participants with CWP were identified. Logistic regression estimated the odds ratio, with 95%
confidence intervals, of CWP in the NP and NP groups compared with no pain, and NP compared with NP. Partial population
attributable risks estimated the proportion of CWP attributable to baseline NP or NP exposure. One thousand one hundred sixty-
two participants completed the baseline DN4 and provided pain data at follow-up: 523 (45.0%) had no baseline pain, 562 (48.4%)
NP, and 77 (6.6%) NP. One hundred fifty-three (13.2%) had CWP at 12 months: 19 (3.6%) no pain, 108 (19.2%) NP, and 26
(33.8%) NP. NP (2.9 [1.9-4.3]) and NP (2.1 [1.1-4.0]) predicted CWP after adjusting for demographics, Hospital Anxiety and
Depression scale, Pittsburgh SleepQuality Index, andmedications. The partial population attributable risk was 41.3% (25.2-54.0)
for NP and 6.0% (0.1-11.6) for NP. The NP group were not more likely to develop CWPwhen compared directly with NP (1.5 [0.8-
2.8]). Neuropathic pain was relatively rare and predicted a small number of new-onset CWP cases. Using these estimates,
treatments targeting NP would at best prevent 6% of CWP cases.
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1. Introduction
Chronic widespread pain (CWP), the clinical hallmark of
fibromyalgia,47 is a significant health burden: it affects 11% of
the general population,31 is associated with higher disability,44
and increases mortality30 most likely through reduced physical
function.40 Of the estimated 33% to 50%7,44 of the general
population who have a painful regional musculoskeletal disorder
(eg, back pain and knee pain), up to 20% develop CWP.20,33,34
Risk factors for CWP include sleep problems,1 childhood chronic
physical illness,37 and trauma.23 In a systematic review, the
transition from regional musculoskeletal pain to CWP was
predicted by pain independently of sex, increasing age, family
history of pain, and depression.28
Neuropathic pain (NP), pain distinguished from other pain
conditions by characteristic symptoms such as “burning” or
“freezing,”11,14 is present in up to 16% of persons with CWP,35
double the population prevalence of 8%.15 The heritability of NP
and CWP is correlated and the genetic predisposition to NP
shared with CWP.35 There are no prospective studies testing
whether the risk of developing CWP in those with regional pain is
augmented by the presence of NP.
This study tested the hypothesis that the risk of developing CWP
would be augmented by the presence of pain with symptoms of NP.
2. Methods
In a prospective population-based cohort study (the Pain across
the Adult Lifespan study8), participants were invited to complete
a baseline questionnaire. Those free of CWP were identified and
classified as having no pain, pain without neuropathic symptoms
(NP), or NP. All participants were followed up 12 months later, at
which time they completed a second questionnaire and those
with CWP identified. The relationship between pain status at
baseline and CWP at follow-up was examined.
Ethical approval was granted by the North West 8 Research
Ethics Committee—Greater Manchester East (reference number
10/H1013/29).
2.1. Baseline questionnaire
The baseline questionnaire collected data on the presence,
location, and duration of pain. Participant’s reports of pain
were used to identify those with prevalent CWP, classified using
published criteria13 that have been used in previous
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population-based surveys24 (see below for details). The screening
questionnaire also collected data on demographics (date of birth;
sex; English Index of Multiple Deprivation 2007,38 with higher
scores indicating less deprivation;Hospital Anxiety andDepression
(HAD)48 depression andanxiety subscales (7 itemseach, scored 0-
3, total score 0-21, higher scores represent higher probability of
depression or anxiety); Pittsburgh Sleep Quality Index10 (19 items,
scored 0-3, total score range 0-57); Rapid Assessment of Physical
Activity42 (7 items, scored as sedentary, underactive, underactive
regular, and active); self-reported pain medications (summed to
give a total count); and signed consent.
2.2. Presence, distribution, and duration of
musculoskeletal pain
The questionnaire included a detailed assessment of the
presence of musculoskeletal pain. All participants were asked
“During the past month, have you experienced any pain which
has lasted at least 1 day or longer?” Respondents answering
positively were asked to shade the location(s) of their pain on
a four-view body manikin. Participants were then asked
whether they had been aware of their pain for 3 months or
longer (yes/no). Using their responses to these questions,
participants were classified as having CWP using the definition
in the American College of Rheumatology (ACR) 1990
classification criteria for fibromyalgia47 that was operational-
ised by Croft et al.13 as requiring axial (cervical spine, thoracic
spine, anterior chest, or low back) pain and pain in contralat-
eral body quadrants, above and below the waist, and on the
right and left hand sides of the body, which has been present
for at least 3months. Remaining participants were classified as
having some pain (those participants reporting pain that did
not satisfy the criteria for CWP) or no pain. The data collection
tool (a blank body manikin) has been shown to collect valid and
reliable pain data with high between-rater reliability scoring.27
The original criteria for CWP defined by Croft et al.13 were
based on the definition included in the 1990 classification
criteria for fibromyalgia that required pain in the axial skeleton
and in contralateral body quadrants. The criteria have been
used inmultiple population-based epidemiological studies and
have face and construct validity (they identify persons with high
care utilisation, poor sleep, depression, physical inactivity, and
with higher tender point counts among many other findings)
9,26 and have been shown to identify persons with a genetic
susceptibility to developing CWP.29,39
2.3. Neuropathic pain
Participants reporting the presence of pain were invited to report
the sensory characteristics of their pain symptoms using the
Douleur Neuropathique 4 (DN4) questionnaire.5 Participants
were asked “Thinking about your single worst pain, does the
pain have one or more of the following characteristics?”;
burning, painful cold, electric shocks, tingling, pins and needles,
numbness, and itching. For each characteristic responses were
scored yes (51) or no (50). Participants scoring 3 or more were
considered to have pain of predominantly neuropathic origin.
The short version of the DN4 has been validated for use in self-
reported questionnaires with 83% sensitivity and 90% specific-
ity when compared to clinical diagnosis.4 The interrater reliability
of the DN4 was demonstrated in the original French version with
kappa values for individual items ranging from 0.66 to 0.965 and
has subsequently been demonstrated cross-culturally, al-
though the level of supporting evidence is low.32
2.4. Follow-up questionnaire
A follow-up questionnaire was mailed to those baseline partic-
ipants who were free of CWP, 12 months after the date they
returned a baseline questionnaire. The follow-up questionnaire
included identical methods to assess pain as those used in the
baseline survey. Based on their pain reports at follow-up,
participants were classified as “CWP” for those who reported pain
that satisfied the criteria for CWP or “Not CWP.”
2.5. Analysis
Logistic regressionestimated theoddsofCWP first in theNP andNP
groups compared with the no pain group (the referent group),
second in the NP group compared with the NP group (the referent
group), and finally for the individual pain characteristics with those
participants not reporting the characteristic being classified as the
referent group. Results were expressed as odds ratios (ORs) with
95% confidence intervals (CIs). For those comparisons with
significant ORs, population attributable risks (PARs) were calculated
using formulae for cohort studies.21,41 These estimated the % of
CWP that would be avoided if participants were not exposed to NP
or NP. In an evaluation of a preventive intervention in a multifactorial
disease setting, the interest is in the percent of cases associatedwith
the exposures to be modified, when other risk factors, possibly
nonmodifiable, exist but do not change as a result of the intervention.
The partial population attributable risk (PARp) was proposed to
estimate this quantity. Under the assumption of no interaction of the
index exposure effectswith the background risk factors, the PARp is
formulated as
PARp ¼ +
S
s¼ 1+
T
t¼ 1pstR1sRR2t2 +
S
s¼ 1+
T
t¼ 1pstRR2t
+Ss¼ 1+
T
t¼ 1pstRR1sRR2t
¼ +
T
t¼ 1pstRR2t
+Ss¼1 +
T
t¼ 1pstRR2t
where t denotes a stratum of unique combinations of levels of
all background risk factors which are not under study, t5 1;…; T
and RR2t is the relative risk in combination t relative to the lowest
risk level, where RR2,1 5 1. S indicates an index exposure group
defined by each of the unique combinations of the levels of the
index risk factors, that is, those risk factors to which the PARp
applies, s5 1;…; S, and RR1s is the relative risk corresponding to
combinations relative to the lowest risk combination, RR1,1 5 1.
The joint prevalence of exposure group s and stratum t is denoted
by pst, and p.t 5 +
s
s51pst.
41
3. Results
3.1. Participation rates
Of 2654 personswhoweremailed a baseline questionnaire, 1817
responded (68.5%, adjusted for 312 [11.8%] participants who
had moved from their recorded address and 41 [1.5%] who had
died) (Fig. 1). One thousand three hundred seventy-seven
(75.8%) participants were free of CWP and were mailed
a follow-up questionnaire, and 1174 (85.3%, adjusted for those
who had moved or died) responded.
3.2. Rate of chronic widespread pain and associated factors
Of the 1174 participants at follow-up, 12 (1.0%) were missing
pain data, leaving 1162 participants for analysis. Of the 1162
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participants, 523 (45.0%) had no pain, 562 (48.4%) had NP,
and 77 (6.6%) had NP at baseline (Table 1). The proportion of
participants classified as CWP at follow-up was significantly
higher among those with NP (19.2%) and those with NP
(33.8%), when compared with the proportion in those reporting
no pain at baseline (3.6%). Baseline reports of NP character-
istics assessed in the DN4 questionnaire were more common in
those with CWP at follow-up (P , 0.001 for all comparisons).
Chronic widespread pain was associated with having signifi-
cantly more pain sites at baseline, higher pain medication use at
baseline, female sex, and higher HAD anxiety, HAD depression,
and sleep problem scores at baseline. There was no
association with age, occupational status, or deprivation score
(Table 1).
3.3. The relationship between neuropathic pain and chronic
widespread pain
When compared to those with no pain at baseline, after
adjusting for age and sex (Table 2), NP was associated with
a 3-fold (OR 5 2.9, 95% CI [2.0-4.2]) increased odds of CWP
at follow-up, and NP was associated with a 4-fold (3.9 [2.3-
6.4]) increased odds. After adjusting for age, sex, psychoso-
cial variables, demographics, and medication use, the
association between NP and CWP persisted (2.9 [1.9, 4.3]),
whereas the association between NP and CWP was attenu-
ated (2.1 [1.1-4.0]). After adjusting for all covariates, the NP
characteristics of burning, electric shocks, tingling, pins and
needles, and numbness were all significantly associated
with CWP.
After adjusting for age and sex, those with NP were twice (2.2
[1.3-3.6]) as likely to have CWP at follow-up when compared with
the NP group (Table 2). However, the relationship between NP
and CWPwas attenuated and no longer significant (1.5 [0.8-2.8])
when adjusted for age, sex, psychosocial variables, demograph-
ics, and medication use.
3.4. Partial population attributable risks
The proportion of all cases of CWP that could be attributed to the
presence of NP at baseline was 6.0% (95% CI [0.1-11.6]),
Figure 1. Flow diagram of participant recruitment andCWP rates. Primary care records were reviewed to identify thosewhowere recorded as either havingmoved
address or had died after the questionnaire mailing. CWP-free 5 CWP-free at baseline and follow-up; CWP 5 CWP-free at baseline and CWP at follow-up;
†Proportions are of participants who sent baseline questionnaire. *Proportions are of participants who returned a baseline questionnaire. ⁰Proportions are of
participants free of CWPat baseline. ⁺Proportions are of participants free of CWPat baseline andmailed a follow-up questionnaire. CWP, chronic widespread pain.
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whereas 41.3% (25.2, 54.0) could be attributed to the presence
of NP (Table 2). The proportion of CWP attributable to the NP
characteristics ranged from 1.9% to 5.0% (Table 2).
4. Discussion
4.1. Summary of findings
This study tested the hypothesis that the relationship between
regional pain and CWPwould be augmented by the presence of
symptoms of NP. The data presented here do not support that
hypothesis. When compared to those persons with no pain,
having some pain was associated with an increased odds of
developing CWP. The relationship with CWP initially seemed to
be stronger among those persons with symptoms of NP,
although the effect was attenuated when adjusted for age, sex,
occupational status, deprivation, anxiety, depression, and sleep
problems to the extent that NP had a stronger relationship with
CWP. The data suggest that, at a population level, the
proportion of all new cases of CWP that could be attributed to
NP was modest, and was lower than the proportion attributable
to NP.
4.2. Setting these results in the context of current literature
The data presented here show that having regional pain
increases the odds of CWP by 2-fold, irrespective of the
presence of NP symptoms. Previous longitudinal studies have
shown similar strengths of associations with arm pain (relative
risk [RR] 2.4 [1.5-4.3]) and back pain (RR 2.5 [1.5-6.7])17 and
pain at multiple sites (OR 2.6 [1.3-5.4])22 with CWP. In contrast
to the findings presented here, some previous cross-sectional
studies have supported the role of NP in CWP and associated
disorders. Fishbain et al.16 reported that chronic pain patients
including those with fibromyalgia scored above the cutoff on the
Neuropathic Pain Scale. Fibromyalgia patients commonly report
sensory symptoms characteristic of NP with 83% reporting
deep-tissue hyperalgesia, 51% reporting burning, and 47%
reporting prickling on the painDETECT questionnaire.2,18 There
is suggestive evidence for an overlap between NP and CWP or
Table 1
Participant characteristics at baseline stratified by chronic widespread pain status at follow-up.
Follow-up pain status P†
Not CWP; N 5 1009 (86.8%) CWP; N 5 153 (13.2%)
Neuropathic pain, no. of pain sites and pain
medication use
Presence of pain at baseline stratified by DN4
score*
No pain 504 (49.9) 19 (12.4) 0.00
NP (regional pain, DN4 score 0-2) 454 (45.0) 108 (70.6)
NP (regional pain, DN4 score 3-7) 51 (5.1) 26 (17.0)
DN4 pain characteristics (n (%) reporting yes)*
Burning 125 (12.4) 48 (31.4) 0.00
Painful cold 46 (4.6) 16 (10.5) 0.00
Electric shocks 75 (7.4) 33 (21.6) 0.00
Tingling 70 (6.9) 31 (20.3) 0.00
Pins and needles 49 (4.9) 23 (15.0) 0.00
Itching 23 (2.3) 8 (5.2) 0.04
Numbness 83 (8.2) 30 (19.6) 0.00
No. of pain sites 1 (0-3) 3 (2-5) 0.00
No. of current pain medications 1 (0-3) 2 (0-5) 0.00
Demographics
Age 61 (53-67) 62 (54-67) 0.43
Sex*
Women 564 (55.8) 99 (64.7) 0.04
Men 446 (44.2) 54 (35.3)
Occupational status*
Working full time 385 (38.2) 47 (31.1) 0.11
Working part time 156 (15.5) 26 (17.2)
Unemployed due to ill health 18 (1.8) 7 (4.6)
Other (including unemployed, n 5 20) 449 (44.4) 71 (47.0)
Deprivation quantiles*
1 202 (20.0) 45 (29.4) 0.05
2 185 (18.3) 22 (14.4)
3 320 (31.7) 41 (26.8)
4 302 (29.9) 45 (29.4)
Psychosocial variables
HAD depression 2 (1-5) 4 (2-7) 0.00
HAD anxiety 4 (2-7) 6 (3-9) 0.00
Sleep problems 5 (2-9) 8 (4-13) 0.00
All values are median (interquartile range) unless indicated by * which are n (%) with column values totalling 100% (except where rounding equals ,100%).
† P values derived from x2 or Kruskal–Wallis tests as appropriate.
CWP, chronic widespread pain; DN4, Douleur Neuropathique 4; HAD, Hospital Anxiety and Depression scale; NP, neuropathic pain.
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fibromyalgia; these disorders share common risk factors
including age, sex, body mass index, smoking, and socioeco-
nomic status.35 However, these associations are not consistent:
patients with painful diabetic neuropathy when compared to
those with fibromyalgia were less likely to be female, had
a higher BMI, were less likely to be depressed or anxious, and
had better sleep patterns.25
Fibromyalgia and CWP are clearly related, with fibromyalgia
being a subset of persons with CWP.46 However, fibromyalgia
is not CWP, and one of the main differences may be the
presence of NP. In a study of twins, 15% of those with CWP
had features of NP, the heritability of NP and CWP were
correlated, and the genetic predisposition to NP was shared
with that of CWP.35 These associations may be driven by the
subset of twins who had fibromyalgia, and this is supported by
the findings of similar results when the data set was restricted
to the subgroup of twins with fibromyalgia.35 The data
presented here support the role of regional pain in the onset
of CWP and clearly show that the relationship is independent of
the presence of NP symptoms. It is possible that some
participants with asymptomatic (ie, not painful) small fibre
neuropathy could be more likely to develop CWP; however, we
did not collect that data and are unable to address that
question in the current study.
4.3. Methodological strengths and limitations
This study has several strengths. The cohort was a large,
unselected group of persons free of CWP at baseline. The
study used validated assessments of pain, NP, and all
covariates. Previous studies that were cross-sectional were
unable to determine the temporal association between the
presence of neuropathic features of acute localised pain and
the transition to CWP. Here, participants who were free of
CWP were identified and followed up over time to identify
those who developed CWP, allowing the temporal relationship
between having NP and developing CWP to be established.
Previous studies have examined clinic populations where
levels of psychological distress are higher than unselected
general population samples, and high levels of psychological
and emotional distress are known to be related to levels of
pain reporting, somatosensory changes, and altered noci-
ceptive processing.45 Limitations were that participants were
followed up once, 12 months after they completed their
baseline questionnaire, and it was not clear what happened in
the intervening months between baseline and follow-up.
Although those reporting CWP at follow-up were identified
and classified as the CWP group, it is likely that some
participants may have developed CWP that then resolved
before follow-up. We would have missed those incident
cases, underestimated the rate of CWP in this cohort, and
misclassified participants as Not CWP instead of CWP. How
would that impact on the associations reported here? If the
misclassification was random across baseline exposure
status (ie, was independent of baseline pain status) it could
act to attenuate the observed association and we may have
underestimated the association between NP and the onset of
CWP. Any underestimation of effect is unlikely to impact
significantly on the pPAR estimates here because, although
the PAR is based on the effect estimate, it is heavily influenced
by how common a risk factor is in the population. Among
those free of CWP, baseline NP was much more common,
with 48.4% of participants having had NP and 6.6%
having NP.
Table 2
Regional pain stratified by DN4 score and DN4 pain characteristics and CWP: results from multinomial logistic regression
models.
Adjustments
Age and sex Age, sex, and
psychosocial variables*
Age, sex, psychosocial
variables, and demographics†
Age, sex, psychosocial variables,
demographics, andmedication use‡
OR
(95% CI)
OR
(95% CI)
OR
(95% CI)
OR
(95% CI)
PARp, %
(95% CI)
Presence of pain at baseline
stratified by DN4 score
No pain Referent Referent Referent Referent Referent
NP(DN4 score 0-2) 2.9 (2.0-4.2) 2.8 (1.9-4.1) 2.8 (1.9-4.2) 2.9 (1.9-4.3) 41.3 (25.2-54.0)
NP (DN4 score 3-7) 3.9 (2.3-6.4) 2.5 (1.4-4.4) 2.3 (1.2-4.2) 2.1 (1.1-4.0) 6.0 (0.1-11.6)
Presence of regional pain at
baseline stratified by DN4 score
NP(DN4 score 0-2) Referent Referent Referent Referent Not estimated
NP (DN4 score 3-7) 2.2 (1.3-3.6) 1.7 (0.96-2.9) 1.6 (0.9-2.9) 1.5 (0.8-2.8)
DN4 pain characteristics§
Burning 3.2 (2.1-4.7) 2.7 (1.8-4.1) 2.7 (1.7-4.2) 2.6 (1.7-4.0) 5.0 (1.1-8.8)
Painful cold 2.5 (1.4-4.6) 1.9 (0.99-3.5) 1.9 (0.97-3.8) 1.8 (0.9-3.5) 1.1 (0.7-2.9)
Electric shocks 3.4 (2.2-5.4) 2.9 (1.8-4.6) 2.6 (1.5-4.4) 2.5 (1.4-4.2) 2.9 (0.0-5.7)
Tingling 3.4 (2.1-5.4) 2.3 (1.4-3.9) 2.3 (1.3-3.9) 2.2 (1.3-3.7) 2.8 (0.0-5.5)
Pins and needles 3.5 (2.1-5.9) 2.3 (1.3-4.1) 2.1 (1.1-3.9) 2.0 (1.1-3.7) 1.6 (0.1-3.8)
Itching 2.3 (1.0-5.3) 1.4 (0.6-3.4) 1.2 (0.5-3.2) 1.0 (0.4-2.8) 0.0 (0.0-1.2)
Numbness 2.8 (1.7-4.4) 2.0 (1.2-3.2) 1.8 (1.1-3.1) 1.8 (1.1-3.1) 1.9 (0.1-4.3)
* Adjustments were age, sex, and baseline measures of depression and sleep problems.
† Adjustments were as for previous model plus baseline measures of occupational status and deprivation.
‡ Adjustments were as for previous model plus baseline measures of number of current pain medications.
§ Referent group are participants not reporting the DN4 pain characteristic.
CI, confidence interval; CWP, chronic widespread pain; DN4, Douleur Neuropathique 4; NP, neuropathic pain; OR, odds ratio; PARp, partial population attributable risk estimated from fully adjusted model.
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Several screening tools have been developed to assess NP
characteristics. Previous studies using the DN4 and LANSS
have estimated the prevalence of pain of predominately
neuropathic origin to be between 7% and 8% of the general
population.6,43 However, the use of NP screening tools in
self-reported surveys of musculoskeletal pain is contentious
because not all pains are the same.36 NP screening tools
have been primarily validated for use in subjects with single-
site pain disorders (such as low back pain, diabetic
neuropathy, or trigeminal neuralgia) and require the re-
spondent to focus on a single painful region or area.3,5,18
Although the participants in this study did not have CWP at
baseline, CWP by its nature is multisite and widespread, and
the suitability of these screening tools for use in studies of
multisite pain conditions is not clear.36 A recent epidemio-
logical survey of NP symptoms in the general population
navigated this issue by asking participants to indicate the
site(s) of any chronic pain on a body map and then to identify
the most troublesome site of pain from a list of body regions,
and subsequent questions on neuropathic symptoms were
focused on this “most troublesome pain.”43 That is, the
method we used here, and although this method is not
without its shortcomings, it does allow for the assessment of
NP symptoms in population-based surveys of musculoskel-
etal pain which would otherwise not be possible.
4.4. Clinical implications
The effectiveness of pharmacological treatments for NP in
patients with CWP disorders such as fibromyalgia are not clear
with systematic reviews showing the supporting evidence for
gabapentin is weak,12 and there are no high-quality trials of
oxycodone.19 In this study, NP was relatively rare and predicted
a small number of new-onset CWP cases. Using these estimates,
treatments targeting NPwould at best prevent 6%of CWP cases.
Chronic widespread pain is highly prevalent in the general
population, and effective treatment of pain not of NP origin will
have the biggest impact on population levels of CWP.
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